1. Homepage
  2. Equities
  3. Israel
  4. TEL AVIV STOCK EXCHANGE
  5. Evogene Ltd.
  6. Company
    EVGN   IL0011050551

EVOGENE LTD.

(EVGN)
  Report
Delayed TEL AVIV STOCK EXCHANGE  -  03:25 2022-08-11 am EDT
337.30 ILa   +4.91%
08/03EVOGENE : NOTICE OF 2022 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON SEPTEMBER 8, 2022 - Form 6-K
PU
07/29Biomica Appoints Professor Gal Markel to Company's Scientific Advisory Board - Evogene
AQ
07/28EVOGENE : Other Report or Announcement
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsRevisions 
Business Summary
Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.

Number of employees : 141 people.
Sales per Business
20202021Delta
Agriculture2.9181.4%2.0367.5% -30.36%
Human Health0.267.2%0.5919.7% +129.18%
Unallocated0.298.2%0.268.5% -12.7%
Industrial Applications0.113.2%0.134.3% +13.85%
ILS in Million
Sales per region
20202021Delta
United States2.3265%1.6856% -27.64%
Israel0.7922%1.1438% +45.08%
Others0.072%0.124% +67.98%
Brazil0.3911%0.062% -84.73%
ILS in Million
Managers
Name Title Age Since
Ofer Haviv Chief Financial & Operational Officer 55 2002
Yaron Eldad Chief Financial Officer 54 2022
Mark Kapel Chief Technology Officer 45 -
Eyal Emmanuel, Dr. Vice President-Corporate Strategy 48 2018
Rivka Neufeld Manager-Investor Relations - 2019
Nir Arbel, Dr. Chief Product Officer - 2021
Sassi Masliah Executive Vice President-Corporate Development - 2022
Eyal Ronen Executive Vice President-Business Development - 2022
Liat Foigel Wejgman Director-Human Resources - 2015
Yisrael Gewirtz Internal Auditor 45 -
Members of the board
Name Title Age Since
Sarit Firon Chairman 55 2021
Leon Y. Recanati Independent Director 73 2005
Ziv Kop Independent Director 51 2014
Adrian Percy Independent Director 56 2019
Oded Shoseyov, Dr. Independent Director 66 2018
Dan Michael Falk Director 77 2021
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 41,215,944 38,700,359 93.9% 0 0.0% 93.9%
Shareholders
NameEquities%
ARK Investment Management LLC 3,611,842 8.77%
Ivy Investment Management Co. 2,757,223 6.69%
Waddell & Reed Investment Management Co. 1,155,062 2.80%
Alpha Capital Anstalt 1,038,720 2.52%
Leon Y. Recanati 838,860 2.04%
Goldman Sachs International 767,184 1.86%
Martin S. Gerstel 636,506 1.55%
Renaissance Technologies LLC 459,081 1.11%
Canada Pension Plan Investment Board 400,000 0.97%
Morgan Stanley & Co. LLC 298,885 0.73%
Company contact information
Evogene Ltd.
13 Gad Feinstein Street
Park Rehovot
Rehovot, HaMerkaz 76121

Phone : +972.8.931.1900
Fax : +972.8.946.6724
Web : http://www.evogene.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Evogene Ltd.